Loading clinical trials...
Loading clinical trials...
To evaluate the efficacy and safety of CM336 (BCMA/CD3 Bispecific Antibody) in the treatment of patients with relapsed or refractory autoimmune cytopenia
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Keymed Biosciences Co.Ltd
NCT07039422 · Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
NCT04645199 · Multiple Myeloma, Acute Myeloid Leukemia, and more
NCT07361094 · Relapsed/Refractory Systemic Lupus Erythematosus, Relapsed/Refractory Systemic Sclerosis, and more
NCT07294365 · Immune Thrombocytopenia (ITP)
NCT06888960 · Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), and more
Henan Cancer Hospital
Zhengzhou, Henan
Heping Hospital Affiliated to Changzhi Medical College
Changzhi, Shanxi
Blood Disease Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions